FRANK KARBE - 05 Jul 2022 Form 4 Insider Report for Better Therapeutics, Inc.

Role
Chief Executive Officer, President, Treasurer and Secretary, Director
Signature
/s/ Mark Heinen, Attorney-in-Fact
Issuer symbol
BTTX on OTC
Transactions as of
05 Jul 2022
Net transactions value
$0
Form type
4
Filing time
07 Jul 2022, 16:32:20 UTC
Previous filing
27 May 2022
Next filing
15 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) Award $0 +472,200 $0.000000 472,200 05 Jul 2022 Common Stock 472,200 $1.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/4 of the shares subject to the stock option on July 5, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on July 5, 2022.

Remarks:

Chief Executive Officer, President, Treasurer and Secretary